Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery
Key facts
- Who runs it
- Weill Medical College of Cornell University
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- Dec 2020
- Expected to end
- Oct 2030
- Type of study
- Interventional, 5 groups
- Treatments tested
- AdVEGF-All6A+
- AdNull
- Record updated
- 27 January 2021
- Why it stopped
- Closure due to lack of funding.
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 44 criteriaShow less
Who can take part
- Males and females, age 18 to 90
- Demonstrable reversible left ventricular ischemia in viable myocardium as assessed by ST segment/T wave abnormalities detected by exercise testing with 99mTc-sestamibi single-photon emission computed tomography (SPECT) prior to and following the exercise test
- Individuals who have coronary artery disease (CAD) but have angina refractory to medical therapy
- Individuals who experience angina class II-IV as defined by the Canadian Cardiovascular Society
- Individuals who have had a coronary angiogram in the prior 6 months demonstrating diffuse coronary artery disease and are not considered to be eligible for coronary artery bypass surgery, stents, or angioplasty, because of the lack of suitable target lesions
- Individuals must be medically capable of undergoing open thoracotomy
- Individuals must have neutralizing anti-adenovirus serotype 5 titer ≤160; this criteria is based on the knowledge that some individuals have high anti Ad5 neutralizing antibody titer which may limit efficacy
- Hematocrit >30%
- WBC <10,000
- Normal prothrombin, partial thromboplastin time (excluding IV heparin therapy)
- Normal liver-related serum parameters
- Glomerular filtration rate (GFR) > 30 ml/min
- No evidence of active infection of any types, including adenovirus, hepatitis virus (A, B or C) or human immunodeficiency virus
- No evidence of central nervous system, major psychiatric, musculoskeletal or immune disorder
- No allergy to the vehicle used to suspend the virus or contrast materials used in radiographic procedures
- Fertile or infertile individuals; it will be recommended that fertile individuals utilize barrier birth control measures to prevent pregnancy during and for 2 months following the administration of the vector
- Individuals not receiving experimental medications or participating in another experimental protocol for at least 4 weeks prior to entry to the study
- Individuals must be able to exercise for at least 90 seconds but no more than 15 min on a modified Bruce protocol exercise treadmill test while exhibiting angina with concurrent 1 mm horizontal or downsloping ST-segment depression
- The study individual must be able to undergo the procedures in the protocol
- Willingness to participate in the study
- Capable of providing informed consent
Who cannot take part
- Individuals receiving corticosteroids or other immunosuppressive medications
- Prior cardiac transplantation
- Prior participation in cardiac gene and/or cardiac cell therapy
- Individuals in whom participation in the study would compromise the normal care and expected progression of their disease
- Individuals with uncontrolled diabetes
- Diabetic individuals with significantly abnormal ophthalmologic exam (moderate or greater disease severity)
- Recent (<6 wk) transmural myocardial infarction
- Unable to undergo cardiac MRI with gadolinium contrast
- Untreated malignant ventricular arrhythmia
- Valvular heart disease requiring surgical intervention
- Uncontrollable asthma or chronic obstructive pulmonary disease (COPD)
- Greater than first degree heart block or sinus node dysfunction without a functional pacemaker
- Known hypersensitivity to adenosine
- Individuals with hypercholesterolemia (LDL above 190 mg/dl or total cholesterol above 240 mg/dl)
- Evidence of infection defined by elevated white blood cell (WBC) count, temperature >38.5ºC, infiltrate on chest x-ray
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values 2.5 greater than normal limits
- Preoperative congestive heart failure (New York Heart Association Function Class III or IV or ejection fraction (EF) <25%
- Individuals who do not meet the inclusion criteria will be unable to participate in the protocol
- Body mass index >35
- Recent (<6 wk) cerebral vascular accident
- Electrocardiograph abnormalities that would interfere with ST-segment analysis
- Systolic blood pressure less than 90 mmHg
- Pregnancy or currently lactating
About the trial
What the trial wants to find out
The proposed Phase I/II clinical trial will be used to determine the safety and toxicity of direct administration of the vector AdVEGF-All6A+ to the ischemic myocardium and to generate preliminary evidence regarding whether direct administration of AdVEGF-All6A+ to the ischemic myocardium will induce growth of collateral blood vessels and improve cardiac function. This is a three-part, multinational/multi-center, placebo controlled study.
The 5 groups in the trial
- Part A, Group 1 - 10^8 puTreatment being tested
Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10\^8, 10\^9, and 10\^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10\^8 particle units.
Treatment: AdVEGF-All6A+
- Part A, Group 2 - 10^9 puTreatment being tested
Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10\^8, 10\^9, and 10\^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10\^9 particle units.
Treatment: AdVEGF-All6A+
- Part A, Group 3 - 10^10 puTreatment being tested
Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10\^8, 10\^9, and 10\^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10\^10 particle units.
Treatment: AdVEGF-All6A+
- Part B, Group 1 - AdVEGF-All6A+Treatment being tested
Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A.
Treatment: AdVEGF-All6A+
- Part B, Group 2 - AdNull placeboTreatment being tested
Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector.
Treatment: AdNull
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase I/II Study, Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor to the Ischemic Myocardium...
- Record updated
- 27 January 2021